Appili Therapeutics (APLIF) News Today $0.01 +0.00 (+16.22%) As of 05/27/2025 12:19 PM Eastern Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesShort InterestBuy This Stock APLIF Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Saptalis Pharmaceuticals Announces the Launch of LIKMEZ® — The First and Only US FDA-Approved Ready-to-Use Oral Suspension of MetronidazoleMay 20, 2025 | finance.yahoo.comAppili Therapeutics Provides Update on Arrangement with Aditxt, Inc.May 19, 2025 | globenewswire.comAppili Therapeutics and Colleagues Publish Manuscript on the Prevention and Emergency Response to TularemiaMay 1, 2025 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZApril 28, 2025 | finanznachrichten.deAppili Therapeutics Announces New Patents Granted for Commercial Stage Asset LIKMEZ®™April 28, 2025 | globenewswire.comAppili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025April 2, 2025 | financialpost.comAppili President and CEO, Don Cilla to Join Aditxt CEO, Amro Albanna for Aditxt Weekly Update on April 4, 2025April 2, 2025 | globenewswire.comUpcoming Aditxt Weekly Update to Highlight Pearsanta’s Acquisition of the Adductomics-Based CaSe Platform and its Potential for Early Cancer DetectionMarch 30, 2025 | businesswire.comAppili Therapeutics announces submission of government funding proposalsMarch 19, 2025 | markets.businessinsider.comAppili Therapeutics Announces Submission of U.S. Federal Government Funding Proposals and Provides Corporate and Aditxt Transaction UpdateMarch 18, 2025 | globenewswire.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2025February 14, 2025 | globenewswire.comAditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern TimeFebruary 13, 2025 | businesswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.November 19, 2024 | finanznachrichten.deAppili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.November 19, 2024 | globenewswire.comAppili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025November 14, 2024 | globenewswire.comAditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of ShareholdersNovember 7, 2024 | finance.yahoo.comAppili Therapeutics Announces Results of Special Meeting of ShareholdersNovember 6, 2024 | globenewswire.comBiopharma Bucking Market Trends on Positive FDA FeedbackNovember 1, 2024 | msn.comAppili Therapeutics announces FDA alignment on ATI-1801 NDA requirementsNovember 1, 2024 | markets.businessinsider.comAditxt announces ‘positive’ FDA feedback for Appili Therapeutics ATI-1801November 1, 2024 | markets.businessinsider.comAppili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA SubmissionOctober 31, 2024 | globenewswire.comAppili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024October 17, 2024 | globenewswire.comAppili Therapeutics – Press Release CorrectionOctober 10, 2024 | globenewswire.comAppili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of ShareholdersOctober 10, 2024 | globenewswire.comAditxt Delivers Shareholder Update and 2024 Year-End PlanOctober 3, 2024 | finance.yahoo.comAppili Therapeutics Inc (APLI)October 2, 2024 | investing.comAppili Therapeutics Announces Results of Annual and Special Meeting of ShareholdersSeptember 17, 2024 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with AditxtAugust 21, 2024 | finanznachrichten.deAditxt Announces Third Amendment to Arrangement Agreement with Appili TherapeuticsAugust 21, 2024 | tmcnet.comAppili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with AditxtAugust 21, 2024 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025August 14, 2024 | finanznachrichten.deAppili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2025August 13, 2024 | globenewswire.comAditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the AcquisitionJuly 25, 2024 | finance.yahoo.comAppili Therapeutics Announces Second Amendment to Arrangement AgreementJuly 18, 2024 | globenewswire.comAppili Therapeutics Announces Amendment to Arrangement Agreement and Increase to Bridge LoanJuly 2, 2024 | globenewswire.comAppili Therapeutics Reports Fiscal Year 2024 Financial and Operational ResultsJune 25, 2024 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 27, 2024 | finanznachrichten.deAppili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 26, 2024 | finance.yahoo.comAppili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.April 26, 2024 | globenewswire.comAppili Therapeutics Inc. (APLIF)April 18, 2024 | finance.yahoo.comAditxt to acquire Appili Therapeutics in strategic moveApril 4, 2024 | uk.investing.comAditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)April 2, 2024 | businesswire.comAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.April 2, 2024 | finance.yahoo.comAppili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.April 2, 2024 | globenewswire.comResearchers Publish Manuscript on the Prevention and Emergency Response to Tularemia OutbreaksMarch 12, 2024 | globenewswire.comAppili Therapeutics Inc.: Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 14, 2024 | finanznachrichten.deAppili Therapeutics reports Q3 resultsFebruary 14, 2024 | seekingalpha.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 13, 2024 | finance.yahoo.comAppili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2024February 13, 2024 | globenewswire.comAppili Therapeutics Inc Ordinary SharesFebruary 3, 2024 | morningstar.com Get Appili Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLIF and its competitors with MarketBeat's FREE daily newsletter. Email Address APLIF Media Mentions By Week APLIF Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APLIF News Sentiment▼0.001.03▲Average Medical News Sentiment APLIF News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APLIF Articles This Week▼00▲APLIF Articles Average Week Get Appili Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLIF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies INDP News SNGX News NRBO News ATNF News AEON News EYEN News ADIL News ONCO News ULUR News EVOK News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (OTCMKTS:APLIF) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Appili Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Appili Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.